Description
Everyone talks about China’s healthcare market, about its size, about its fast and diverse development and about its rapid maturation and change (in terms of legal and regulatory environment). On the other hand, not many have visited the market yet – old stereotypes die hard!
Choosing an “exclusive distributor” seems to be the best way to enter the Chinese market for many. However, this choice is rather driven by fear to put intellectual property in danger or to overcome the apparent complexity of the Chinese regulatory institutions (e.g. NMPA, former CFDA) or by the believe that Joint Ventures always require an at least 50% stake by the Chinese shareholder.
What is the new reality in the Chinese healthcare market? What best practises are there today? What are the new and future healthcare hotspots in China – especially Greater Bay Area? Why and how is China becoming a more and more important element of any internationalisation strategy – especially in light of recent market and regulatory developments?
This internationalisation crash course will offer you a reality check on China’s Healthcare market in the 2020s and it will challenge what you believe you know about the Chinese and international healthcare market.
Program
13:00 Welcome and Introduction - Annalisa Zuccotti, BioRN and Daniel Frerichs, Huangpu District - Guangzhou Development District
- China Opportunities & Internationalisation Strategies in the 21. Century – Jan Gradel, Sino German Hi Tech Park Holding GmbH
- Greater Bay Area Healthcare Footprint- Mos Moo (tbc), Merck China
- China Market Entry – Reality Check 2021 - Daniel Frerichs, Huangpu District - Guangzhou Development District
14:00 Success Story from Huangpu - Malcolm Richardson, Chief Scientist at Richardson Bio Tech 14:15 Case Study, tba
14:30 Q&A Session
You can set-up 1:1 Consulting meeting with Daniel Frerichs before or after the event!
Location and date
Virtual Event